A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects - Trial NCT06303648
Access comprehensive clinical trial information for NCT06303648 through Pure Global AI's free database. This Phase 1 trial is sponsored by Transcend Therapeutics and is currently Recruiting. The study focuses on Post Traumatic Stress Disorder. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Transcend Therapeutics
Timeline & Enrollment
Phase 1
Mar 20, 2024
May 11, 2024
Primary Outcome
Cmax: Maximum Observed Plasma Concentration for methylone,AUC: Area under the plasma concentration-time curve for methylone
Summary
This is an open-label, single, ascending dose study evaluating the PK and safety of methylone
 in healthy subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06303648
Non-Device Trial